Infusion pumps company InfuSystem Holdings Inc (NYSE American:INFU) revealed on Thursday the election of Richard DiIorio as its president and chief executive officer.
Effective immediately, DiIorio has been elected to serve on the company's board of directors and the Office of the President will cease to operate.
Prior to the promotion, DiIorio has served as a member of the company's Office of the President since May 2017 as well as general manager of Oncology since December 2016.
Previously at the company, DiIorio has served as executive vice president of Oncology Sales from July 2014 to November 2016, regional vice president and vice president Strategic Development from August 2010 to July 2014 as well as territory manager until July 2010.
Earlier in his career, DiIorio held various sales and sales leadership roles at Stryker Medical, Novartis Pharmaceuticals as well as Thermo Scientific.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval